Clinical usefulness of anti-α3Gal immunoglobulin E assays for cetuximab-mediated anaphylaxis in head and neck cancer.

ABSTRACT:

Background

Fatal anaphylactic reactions to cetuximab remain a clinical issue, although they are associated with preexisting immunoglobulin E (IgE) directed against the galactose-α1,3-galactose epitope (α3Gal). We aimed to compare the clinical usefulness of the two assays and determine the prevalence of preexisting anti-α3Gal IgE.

Patients and methods

An anti-α3Gal IgE assay was developed (70BP assay) and compared with a commercial assay [bovine thyroglobulin (bTG) assay]. Both assays were applied to two cohorts: 299 healthy blood donors and 41 patients with head and neck cancer treated with cetuximab, including four patients with a history of anaphylactic reaction (9.8%).

Results

The prevalence of anti-α3Gal IgE was 6% and 5% using 70BP and bTG assays, respectively, i

SUBMITTER: Pointreau Y 

PROVIDER: S-EPMC11919289 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature